Active Specific Immunotherapy of Melanoma with a GM3 Ganglioside-Based Vaccine-Reference-Cited by-同舟云学术

Active Specific Immunotherapy of Melanoma with a GM3 Ganglioside-Based Vaccine

Published:2004-11 Issue:6 Volume:27 Page:442-451
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:Journal of Immunotherapy

Author:

Guthmann Marcelo D.,Bitton Roberto J.,Carnero Ariel J. L.,Gabri Mariano R.,Cinat Gabriela,Koliren Leonardo,Lewi Daniel,Fernandez Luis Enrique,Alonso Daniel F.,Gómez Daniel E.,Fainboim Leonardo

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference38 articles.

1. VACCINES AND OTHER ADJUVANT THERAPIES FOR MELANOMA

2. High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

3. Gangliosides of Human Melanoma2

4. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing potential role of gangliosides in immunomodulation and cancer therapeutics;Life Sciences;2024-08

2. Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies;Biomedicine & Pharmacotherapy;2024-07

3. Engineered display of ganglioside-sugars on protein elicits a clonally and structurally constrained B cell response;2023-06-06

4. Mimicry of Tumour-Associated Carbohydrates: Is It a Promising Option for Cancer Treatment?;Immuno;2023-03-23

5. Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives;Cancers;2020-10-27